GRx+Biosims - No-cost FDA workshop limited to first 100 who sign up. Act now!

New White Paper: Access Denied

AAM's "Access Denied" white paper highlights new data on the treatment of generic medicines in Medicare Part D, resulting in patients paying more for their medicines even when lower-priced FDA-approved generics and biosimilars are available.

Read Press Release
AAM's 2019 Access & Savings in the U.S. Report

The quality and affordability of generic medicines makes possible greater access, adherence and improved health for millions of patients across the United States.

Read Report
More Speakers + Opportunities

It's shaping up to be the best lineup ever at GRx+Biosims 2019 with more than 40 influential speakers you don’t want to miss.

View Agenda
How Much Did Your State Save?

Take a deeper look at state-by-state generic drug savings from the 2019 Generic Drug and Biosimilars Access & Savings in the U.S. report.

Read Blog
NAFTA 2.0: Obstacles to More Affordable Medicines

The U.S.-Mexico-Canada Agreement (USMCA) or "NAFTA 2.0" contains obstacles to more affordable meds for Americans. There is still time to #FixUSMCA to put America’s patient first!

View Infographic

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of current drugs and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Sep 20, 2019 | Craig Burton

White Paper: Access Denied: Why New Generics Are Not Reaching America's Seniors

Sep 20, 2019 | Rachel Schwartz

Seniors Denied Access to New, Lower-Priced Generic Drugs Due to Medicare Coverage Delays

White Paper: Biosimilars Council Failure to Launch Part 2

Sep 9, 2019 | Craig Burton

White Paper Part 2: Failure to Launch: Barriers to Biosimilar Market Adoption

Video

Sep 9, 2019 | Erica Klinger

AAM's Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track

Aug 26, 2019 | Erica Klinger

Giving, Volunteering and More: How Our Members Show They Care

Jul 30, 2019 | Ashlie Van Meter

A Generic Summer Savings Tour: How Did Your State Do?